Levin Group (United States)

Sewing garments using robots has consistently posed a research challenge due to the inherent complexities in fabric manipulation. In this paper, we introduce an intelligent robotic automation system designed to address this issue. By employing a patented technique that temporarily stiffens garments, we eliminate the traditional necessity for fabric modeling. Our methodological approach is rooted in a meticulously designed three-stage pipeline: first, an accurate pose estimation of the cut fabric pieces; second, a procedure to temporarily join fabric pieces; and third, a closed-loop visual servoing technique for the sewing process. Demonstrating versatility across various fabric types, our approach has been successfully validated in practical settings, notably with cotton material at the Bluewater Defense production line and denim material at Levi’s research facility. The techniques described in this paper integrate robotic mechanisms with traditional sewing machines, devising a real-time sewing algorithm, and providing hands-on validation through a collaborative robot setup.

As early and effective antiretroviral therapy has become more widespread, HIV has transitioned from a progressive, fatal disease to a chronic, manageable disease marked by elevated risk of chronic comorbid diseases, including cardiovascular diseases (CVDs). Rates of myocardial infarction, heart failure, stroke, and other CVD manifestations, including pulmonary hypertension and sudden cardiac death, are significantly higher for people living with HIV than for uninfected control subjects, even in the setting of HIV viral suppression with effective antiretroviral therapy. These elevated risks generally persist after demographic and clinical risk factors are accounted for and may be partly attributed to chronic inflammation and immune dysregulation. Data on long-term CVD outcomes in HIV are limited by the relatively recent epidemiological transition of HIV to a chronic disease. Therefore, our understanding of CVD pathogenesis, prevention, and treatment in HIV relies on large observational studies, randomized controlled trials of HIV therapies that are underpowered to detect CVD end points, and small interventional studies examining surrogate CVD end points. The purpose of this document is to provide a thorough review of the existing evidence on HIV-associated CVD, in particular atherosclerotic CVD (including myocardial infarction and stroke) and heart failure, as well as pragmatic recommendations on how to approach CVD prevention and treatment in HIV in the absence of large-scale randomized controlled trial data. This statement is intended for clinicians caring for people with HIV, individuals living with HIV, and clinical and translational researchers interested in HIV-associated CVD.

Philadelphia, Pa. From the Department of Orthopaedic Surgery, Perelman School of Medicine at the University of Pennsylvania. Received for publication October 19, 2017; accepted October 24, 2017. Disclosure:The author has no financial interest to declare in relation to the content of this Discussion or of the associated article. L. Scott Levin, M.D., Department of Orthopaedic Surgery, 3737 Market Street, 6th Floor, Philadelphia, Pa. 19104, [email protected]